Development of a multivariable improvement measure for gout.
Naomi SchlesingerN Lawrence EdwardsAnthony E YeoPeter E LipskyPublished in: Arthritis research & therapy (2020)
GMIM captures changes in disease activity in response to treatment with pegloticase and may serve as an evidence-based tool for assessment of responses to other urate-lowering therapies in gout patients.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- ejection fraction
- rheumatoid arthritis patients
- uric acid
- newly diagnosed
- ankylosing spondylitis
- chronic kidney disease
- prognostic factors
- juvenile idiopathic arthritis
- patient reported outcomes
- combination therapy
- replacement therapy